Replimune Group Inc. (REPL)
NASDAQ: REPL
· Real-Time Price · USD
9.54
0.39 (4.26%)
At close: Jul 02, 2025, 3:59 PM
9.70
1.68%
After-hours: Jul 02, 2025, 04:56 PM EDT
4.26% (1D)
| Bid | 9.19 |
| Market Cap | 735.41M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -247.3M |
| EPS (ttm) | -3.07 |
| PE Ratio (ttm) | -3.11 |
| Forward PE | -3.18 |
| Analyst | Buy |
| Ask | 9.7 |
| Volume | 1,087,356 |
| Avg. Volume (20D) | 1,235,865 |
| Open | 9.20 |
| Previous Close | 9.15 |
| Day's Range | 9.15 - 9.70 |
| 52-Week Range | 6.44 - 17.00 |
| Beta | 0.61 |
About REPL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol REPL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for REPL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Replimune Group Inc. is scheduled to release its earnings on Aug 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+6.57%
Replimune Group shares are trading higher after th...
Unlock content with
Pro Subscription
5 months ago
+9.87%
Replimune Group shares are trading higher after HC Wainwright & Co. and BMO Capital raised their respective price targets on the stock.
2 months ago · seekingalpha.com
Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For MelanomaReplimune Group, Inc.'s BLA of RP1 + OPDIVO in advanced melanoma received an FDA Priority Review, with a PDUFA date set for July 22, 2025. RP2, adding an anti-CTLA-4 component, is being tested in meta...